Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$77.53 USD

77.53
2,500,312

+1.25 (1.64%)

Updated Sep 22, 2025 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Zacks Equity Research

Astrazeneca (AZN) Stock Moves -0.69%: What You Should Know

by Zacks Equity Research

Astrazeneca (AZN) closed the most recent trading day at $67.47, moving -0.69% from the previous trading session.

Zacks Equity Research

Apellis (APLS) Files MAA for Pegcetacoplan in GA in Europe

by Zacks Equity Research

Apellis (APLS) submits a marketing authorization application for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration to the European Medicines Agency.

Zacks Equity Research

FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA

by Zacks Equity Research

The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's indication in prostate cancer. The FDA intends to use this time to review the submission.

Zacks Equity Research

Implied Volatility Surging for AstraZeneca (AZN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to AstraZeneca (AZN) stock based on the movements in the options market lately.

Zacks Equity Research

Zacks Industry Outlook Highlights Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca

by Zacks Equity Research

Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca have been highlighted in this Industry Outlook article.

Zacks Equity Research

Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Kinjel Shah headshot

4 Large Drug Stocks to Watch in a Booming Industry

by Kinjel Shah

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.

Zacks Equity Research

Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid

by Zacks Equity Research

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.

Zacks Equity Research

Alnylam (ALNY) Seeks to Expand Onpattro Label in Cardiomyopathy

by Zacks Equity Research

Alnylam (ALNY) initiates label expansion filing with FDA for Onpattro to treat cardiomyopathy in patients suffering from ATTR-amyloidosis. The drug is already approved to treat polyneuropathy in such patients.

Zacks Equity Research

Novartis' (NVS) PNH Candidate Achieves Study Objectives

by Zacks Equity Research

Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.

Zacks Equity Research

Pfizer (PFE) RSV Vaccine Candidate BLA Gets FDA's Priority Tag

by Zacks Equity Research

The FDA's decision on Pfizer's (PFE) BLA seeking approval for RSV vaccine candidate in older adults is expected in May 2023.

Kinjel Shah headshot

Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal

by Kinjel Shah

Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.

Zacks Equity Research

AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal

by Zacks Equity Research

The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies.

Zacks Equity Research

Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

by Zacks Equity Research

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.

Zacks Equity Research

Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Apellis (APLS) Rises on FDA Acceptance of NDA Amendment for GA

by Zacks Equity Research

The FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration. A decision is now due on Feb 26, 2023. Stock up.

Kinjel Shah headshot

Pharma Stock Roundup: RHHBY's Alzheimer's Study Failure, EU Nod for SNY's Enjaymo

by Kinjel Shah

Roche's (RHHBY) late-stage Alzheimer's disease study on key pipeline candidate, gantenerumab fails. Sanofi's (SNY) Enjaymo to treat a rare form of anemia gets approval in Europe.

Zacks Equity Research

Merck (MRK) Outpaces Industry YTD: What's in Store for 2023?

by Zacks Equity Research

Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments keep Merck's (MRK) stock afloat in 2023.

Zacks Equity Research

Key Factors Driving Amgen's (AMGN) Outperformance This Year

by Zacks Equity Research

Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

Zacks Equity Research

Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines

by Zacks Equity Research

Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.

Zacks Equity Research

AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use

by Zacks Equity Research

The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.

Zacks Equity Research

AstraZeneca's (AZN) Imfinzi/Imjudo Combo Gets Another FDA Nod

by Zacks Equity Research

AstraZeneca (AZN) gets its second FDA approval for the Imfinzi+Imjudo combo in non-small cell lung cancer (NSCLC) indication.

Zacks Equity Research

Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort

by Zacks Equity Research

Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.

Kinjel Shah headshot

Pharma Stock Roundup: Q3 Earnings of BAYRY, AZN, EU Nod for AZN, SNY RSV Vaccine

by Kinjel Shah

Bayer (BAYRY) and AstraZeneca (AZN) announce third-quarter results. AstraZeneca and Sanofi's (SNY) RSV vaccine, nirsevimab gets approval in Europe.